

Instructions to Authors

General Policy. IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research. The principal aim of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

Manuscripts will be accepted on the understanding that they report original unpublished works that are not under consideration for publication by another journal, and that they will not be published again in the same form.

All material submitted to IN VIVO will be subject to review, when appropriate, by two members of the Editorial Board. The Editors reserve the right to improve manuscripts on grammar and style.

The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and at all times the animals must be treated humanely. The Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society must be followed.

The Editors and Publishers of IN VIVO accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in IN VIVO, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in IN VIVO, which is a copyrighted publication, the legal ownership of all published parts of the paper has passed from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without written consent of the Managing Editor.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) short papers. Additionally, the Editors may invite review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, glossy prints of the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated on the reverse side. Original karyotypes and photographs should be provided wherever possible, and not photographic copies. Colour plates are charged.

Tables. Each table should be submitted on a separate page, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Nomenclature and Abbreviations. Nomenclature should follow that given in "Chemical Abstracts". Standard abbreviations will be preferable. If a new abbreviation is used, it must be defined at its first usage.

References. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "ISRCTN"). Please note that there is no space between the prefix "ISRCTN" and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by "NCT"). Please note that there is no space between the prefix "NCT" and the number. Example: NCT00001789.

Submission of Manuscripts. Follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your articles twice.):

1. To submit your article online please visit: IIAR-Submissions (link to: <http://www.iar-anticancer.org/submissions/login.php>)
2. You can send your article via e-mail to journals@iar-anticancer.org (mail to: journals@iar-anticancer.org). Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*.doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments.
3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies of your manuscript to the following address:

John G. Delinassios
International Institute of Anticancer Research (IIAR)
Editorial Office of ANTICANCER RESEARCH,
IN VIVO and CANCER GENOMICS & PROTEOMICS
1st km Kapandritiou-Kalamou Road
P.O. Box 22, GR-19014 Kapandriti, Attiki
GREECE

Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors.

Reprints. Twenty-five copies of each communication will be provided free-of-charge. Additional copies or PDF files may be ordered after the acceptance of the paper. Requests for additional reprints should be addressed to the Editorial Office.

Copyright © 2010 International Institute of Anticancer Research (J.G. Delinassios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitter in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

online from January 2009



ANTICANCER RESEARCH

International Journal of Cancer Research and Treatment

ISSN (print): 0250-7005; ISSN (online): 1791-7530

- ANTICANCER RESEARCH is an independent international forum devoted to the rapid publication of original high quality articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months from acceptance are guaranteed.

● Selection of Recent Articles

Overexpression of P150, a Part of the Large Subunit of the Eukaryotic Translation Initiation Factor 3, in Colon Cancer. J. HAYBAECK, T. O'CONNOR, R. SPILKA, G. SPIZZO, CH. ENSINGER, G. MIKUZ, T. BRUNHUBER, A. VOGETSEDER, I. THEURL, W. SALVENMOSER, H. DRAXL, R. BANZIGER, F. BACHMANN, G. SCHAFFER, M. BURGER, P. OBRIST (*Zurich; Zams; Innsbruck; Hall, Austria; Basel, Switzerland*)

Inhibition of Membrane-type 1 Matrix Metalloproteinase Tyrosine Phosphorylation Blocks Tumor Progression in Mice. C. NYALENDO, H. SARTELET, D. GINGRAS, R. BELIVEAU (*Montréal, Québec, Canada*)

Glycolytic Enzyme Inhibitors Affect Pancreatic Cancer Survival by Modulating its Signaling and Energetics. V. BHARDWAJ, N. RIZVI, M.B. LAI, J.C.K. LAI, A. BHUSHAN (*Pocatello, ID, USA*)

Lessons Made of Immune Responses and Vaccines Against Murine Polyomavirus Infection and Polyoma Virus Induced Tumours Potentially Useful for Studies on Human Polyomaviruses. T. RAMQVIST, T. DALIANIS (*Stockholm, Sweden*)

Novel Local Drug Delivery System Using Thermoreversible Gel in Combination with Polymeric Microspheres or Liposomes. T. ARAI, O. BENNY, T. JOKI, L.G. MENON, M. MACHLUF, T. ABE, R.S. CARROLL, P.M. BLACK (*Boston, MA, USA; Haifa, Israel; Tokyo, Japan*)

Superoxide Dismutase 1 Knock-down Sensitizes Cisplatin-resistant Human Ovarian Cancer Cells. J.W. KIM, H. SAHM, J.-S. YOU, M. WANG (*Indianapolis, IN, USA*)

A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) plus Capecitabine (Xeloda) in Advanced Solid Tumors. E. DUGAN, R. TRUAX, K.L. MEADOWS, A.B. NIXON, W.P. PETROS, J. FAVARO, N.H. FERNANDO, M.A. MORSE, G.C. BLOBE, H.I. HURWITZ (*Morgantown, WV, USA*)

Pattern of Failure Following Chemoradiation for Locally Advanced Non-small Cell Lung Cancer: Is There a Role for Stereotactic Body Radiotherapy? N.P. NGUYEN, M. BISHOP, T.J. BOROK, J. WELSH, R. HAMILTON, D. COHEN, L.M. NGUYEN, V.-H. VINCENT (*Dallas; Houston, TX; Ann Arbor, MI, USA; Geneva, Switzerland*)

Unique SNP in CD44 Intron 1 and its Role in Breast Cancer Development. J. ZHOU, P.S. NAGARKATTI, Y. ZHONG, K. CREEK, J. ZHANG, M. NAGARKATTI (*Columbia, SC, USA*)

Calponin h1-S175T Point Mutation Enhances Resistance to Actin Cytoskeleton Perturbation in Human Cancer Cells. A. SUGAYA, M. TAKEOKA, N. ITANO, A. TAGUCHI, T. EHARA, S. TANIGUCHI (*Matsumoto, Japan*)

Smad4 Mediates Mesenchymal - Epithelial Reversion in SW480 Colon Carcinoma Cells. M. POHL, Y. RADACZ, N. PAWLIK, A. SCHOENECK, S. E. BALDUS, J. MUNDING, W. SCHMIEGEL, I. SCHWARTE-WALDHOFF, A. REINACHER-SCHICK (*Bochum; Duesseldorf, Germany*)

Erlotinib in the Treatment of Non-small Cell Lung Cancer: Current Status and Future Developments. C. GRIDELLI, P. MAIONE, M.A. BARESCINO, C. SCETTINO, P.C. SACCO, R. AMBROSIO, V. BARBATO, M. FALANGA, A. ROSSI (*Avellino, Italy*)

Front-line Bevacizumab in Serous Epithelial Ovarian Cancer: Biomarker Analysis of the FINAVAST Trial. P. KARIHTALA, J. MAENPAA, T. TURPEENIEMI-HUJANEN, U. PUISTOLA (*Oulu; Tampere, Finland*)

Cyclin D1b is Present in Human Breast Carcinoma and Co-expression with Cyclin D1a is Associated with Poor Outcome. V.G. ABRAMSON, M. FELDMAN, A.B. TROXEL, Y. WANG, L. SHERMAN, S. MCNALLY, A. DIEHL, A. DeMICHELE (*Philadelphia, PA; Nashville, TN, USA*)

- **Editorial Office:** Manuscripts and correspondence should be addressed to: Dr. John G. Delinassios, Managing Editor, Anticancer Research, Editorial Office, International Institute of Anticancer Research (IIAR), 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki 19014, Greece.
Tel & Fax: +30-22950-53389, e-mail: journals@iiar-anticancer.org. IIAR website: www.iiar-anticancer.org

FREE SPECIMEN COPIES OF ANTICANCER RESEARCH ARE AVAILABLE ON REQUEST

17β-Estradiol Acting as an Electron Mediator: Experiments <i>In Vitro</i> . N. GETOFF, H. SCHITTL, M. GERSCHPACHER, J. HARTMANN, J.C. HUBER, R.-M. QUINT (<i>Vienna, Austria</i>).....	173
Association between <i>CDKN1A</i> Ser31Arg and C20T Gene Polymorphisms and Colorectal Cancer Risk and Prognosis. C. CACINA, İ. YAYLIM-ERALTAN, S. ARİKAN, E.K. SAGLAM, U. ZEYBEK, T. İSBİR (<i>Istanbul, Turkey</i>).....	179
<i>Clinical Studies</i>	
Postinfectious and Chronic Fatigue Syndromes: Clinical Experience from a Tertiary-referral Centre in Norway. H. NAESS, E. SUNDAL, K.-M. MYHR, H.I. NYLAND (<i>Bergen, Norway</i>).....	185
Effect of Atorvastatin on Cellular Adhesion Molecules on Leukocytes in Patients with Normocholesterolemic Coronary Artery Disease. T. WALTER, T. SUSELBECK, M. BORGGREFE, S. SWOBODA, H.M. HOFFMEISTER, C.-E. DEMPFLER (<i>Mannheim; Solingen; Heidelberg, Germany</i>)	189
Spirometric Reference Values in Greek Children and Adolescents. S. ALEXANDRAKI, M. KOUTSILIERIS, N. SIAFAKAS, C. KATSARDIS (<i>Athens; Heraklion, Greece</i>)	195
Development of fMRI Tests for Children with Central Auditory Processing Disorders. S. BARTELFRIEDRICH, Y. BROECKER, M. KNOERGEN, S. KOESLING (<i>Halle/Saale, Germany</i>)	201
Multiple Distant Metastases of Hepatocellular Carcinoma to the Oral Cavity. R.E. FRIEDRICH, J. ZUSTIN (<i>Hamburg, Germany</i>)	211
Iterative Surgical Resection of a Recurrent Gallbladder Carcinoma with Long-term Survival: Report of a Case. S. SCARINGI, G. NESI, T. BARGELLINI, G. BATIGNANI, F. TONELLI (<i>Florence, Italy</i>).....	215
The Use of the Veress Needle to Drain Mammary Periprosthetic Fluid. M. MAZZOCCHI, L.A. DESSY, F. MARCHETTI, F. MARCHETTI, B. CARLESIMO (<i>Perugia; Rome, Italy</i>)	219
The Role of Carbon Dioxide Therapy in the Treatment of Chronic Wounds. C. BRANDI, L. GRIMALDI, G. NISI, A. BRAFA, A. CAMPA, M. CALABRÒ, M. CAMPANA, C. D'ANIELLO (<i>Siena, Italy</i>).....	223
Impact of Adjuvant Chemo- and Radiotherapy on the Cellular Immune System of Breast Cancer Patients. T. MELLIOS, H. LIOE KO, J. BEUTH (<i>Köln, Germany</i>)	227
Complete Recovery from Undertreated Wernicke-Korsakoff Syndrome Following Aggressive Thiamine Treatment. T. PAPARRIGOPOULOS, E. TZAVELLAS, D. KARAIKOS, A. KOUZOUPIS, I. LIAPPAS (<i>Athens, Greece</i>).....	231
Dual-headed Coincidence PET vs. Dedicated PET/CT in the Evaluation of Thoracic Malignancies. S. BERGSTRÖM, G. HOLGERSSON, J.-E. BERGQVIST, M. BERGQVIST, S. EKMAN, M. STENSTRÖM (<i>Gävle; Uppsala; Falun, Sweden</i>)	235
Synchronization of Cortisol Circadian Rhythm by the Pineal Hormone Melatonin in Untreatable Metastatic Solid Tumor Patients and its Possible Prognostic Significance on Tumor Progression. F. BRIVIO, L. FUMAGALLI, G. FUMAGALLI, S. PESCIA, R. BRIVIO, G. DI FEDE, F. ROVELLI, P. LISSONI (<i>Milan; Monza, Italy</i>).....	239
Association of <i>CCL2</i> and <i>CCR2</i> Gene Variants with Endometrial Cancer in Turkish Women. R. ATTAR, B. AGACHAN, S.B. KURAN, C. CACINA, S. SOZEN, L.M. YURDUM, E. ATTAR, T. İSBİR (<i>Istanbul, Turkey</i>).....	243